Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg Ball

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Statistics in Biopharmaceutical Research|June 30, 2021
Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19Mary Nilsson, Brenda Crowe, Greg Anglin, et al.
Blood|May 10, 2003
Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)Simona Gatto, Greg Ball, Francesco Onida, et al.
American Journal of Clinical Pathology|July 2, 2002
Acute lymphoblastic leukemia in elderly patients the Philadelphia chromosome may not be a significant adverse prognostic factorMihaela Onciu, Carlos Bueso-Ramos, L Jeffrey Medeiros, et al.
Contemporary Clinical Trials|July 2, 2019
Bridging blinded and unblinded analysis for ongoing safety monitoring and evaluationLi-An Lin, Yilei Zhan, Hal Li, et al.
Therapeutic Innovation & Regulatory Science|July 12, 2018
Statistical Practices of Safety Monitoring: An Industry SurveyMichael W Colopy, Robert Gordon, Faiz Ahmad, et al.
Therapeutic Innovation & Regulatory Science|January 8, 2024
Aggregate IND Safety Reporting for Smaller Companies and ProgramsGreg Ball, Mengchun Li, Jim Buchanan, et al.
Journal of Diabetes and Its Complications|January 2, 2013
Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitusVivian A Fonseca, Ele Ferrannini, John P Wilding, et al.
Therapeutic Innovation & Regulatory Science|March 17, 2021
Interdisciplinary Safety Evaluation for Learning and Decision-MakingGreg Ball, Barbara A Hendrickson, Amy L Freedman, et al.
Therapeutic Innovation & Regulatory Science|June 20, 2020
A Framework for Safety Evaluation Throughout the Product Development Life-CycleGreg Ball, Tjark Reblin, James Buchanan, et al.
Therapeutic Innovation & Regulatory Science|March 23, 2021
Aggregate Safety Assessment Planning for the Drug Development Life-CycleBarbara A Hendrickson, William Wang, Greg Ball, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Statistics in Biopharmaceutical Research|June 30, 2021
Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19Mary Nilsson, Brenda Crowe, Greg Anglin, et al.
Blood|May 10, 2003
Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)Simona Gatto, Greg Ball, Francesco Onida, et al.
American Journal of Clinical Pathology|July 2, 2002
Acute lymphoblastic leukemia in elderly patients the Philadelphia chromosome may not be a significant adverse prognostic factorMihaela Onciu, Carlos Bueso-Ramos, L Jeffrey Medeiros, et al.
Contemporary Clinical Trials|July 2, 2019
Bridging blinded and unblinded analysis for ongoing safety monitoring and evaluationLi-An Lin, Yilei Zhan, Hal Li, et al.
Therapeutic Innovation & Regulatory Science|July 12, 2018
Statistical Practices of Safety Monitoring: An Industry SurveyMichael W Colopy, Robert Gordon, Faiz Ahmad, et al.
Therapeutic Innovation & Regulatory Science|January 8, 2024
Aggregate IND Safety Reporting for Smaller Companies and ProgramsGreg Ball, Mengchun Li, Jim Buchanan, et al.
Journal of Diabetes and Its Complications|January 2, 2013
Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitusVivian A Fonseca, Ele Ferrannini, John P Wilding, et al.
Therapeutic Innovation & Regulatory Science|March 17, 2021
Interdisciplinary Safety Evaluation for Learning and Decision-MakingGreg Ball, Barbara A Hendrickson, Amy L Freedman, et al.
Therapeutic Innovation & Regulatory Science|June 20, 2020
A Framework for Safety Evaluation Throughout the Product Development Life-CycleGreg Ball, Tjark Reblin, James Buchanan, et al.
Therapeutic Innovation & Regulatory Science|March 23, 2021
Aggregate Safety Assessment Planning for the Drug Development Life-CycleBarbara A Hendrickson, William Wang, Greg Ball, et al.
Pageof 3